Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974293 | 0.90 | MAOB (0.51) | MAOBMAOAPTPN1PTGS2CYP19A1 | |
| SCHEMBL2960730 | 0.83 | MAOB (0.43) | MAOBMAOAPTPN1CA2CMA1 | |
| SCHEMBL140190 | 0.83 | CA2 (0.41) | MAOBMAOAPTPN1CA2FTO | |
| SCHEMBL28392768 | 0.83 | MAOB (0.43) | MAOBMAOAPTPN1CA2CMA1 | |
| SCHEMBL2974161 | 0.83 | MAOB (0.39) | MAOBMAOAPTPN1CA2CMA1 | |
| SCHEMBL6214674 | 0.83 | MAOB (0.39) | MAOBMAOAPTPN1CA2CMA1 | |
| SCHEMBL30824592 | 0.83 | CA2 (0.41) | MAOBMAOAPTPN1CA2FTO | |
| SCHEMBL28394138 | 0.83 | MAOB (0.43) | MAOBMAOAPTPN1CA2CMA1 | |
| SCHEMBL14270019 | 0.79 | TSHR (0.47) | MAOBMAOAPTPN1CA2HSD17B2 | |
| SCHEMBL23627355 | 0.78 | MAOB (0.43) | MAOBMAOAPTPN1CA2FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023244806-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11840550-B2 | Silyl-biaryl phosphoramidites and methods of making | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840550-B2 | Silyl-biaryl phosphoramidites and methods of making | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230372306-A1 | COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR | XOMA (US) LLC | 2023-11-23 | — | — | US | disclosed |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840550-B2 | Silyl-biaryl phosphoramidites and methods of making | PAICS, PGLS, SCLY | MAOB 1523/4885MAOA 2165/4885PTPN1 4119/4885 |
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | MAOB 2172/4885MAOA 3534/4885PTPN1 2018/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | MAOB 2077/4885MAOA 3041/4885PTPN1 1187/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | MAOB 4347/4885MAOA 4268/4885PTPN1 716/4885 |
| US-20230372306-A1 | COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR | PGF, TRPV2, TRPV3 | MAOB 3351/4885MAOA 3653/4885PTPN1 4284/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | MAOB 4708/4885MAOA 4736/4885PTPN1 1496/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | MAOB 2005/4885MAOA 1344/4885PTPN1 4876/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | MAOB 1085/4885MAOA 1297/4885PTPN1 3249/4885 |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | MAOB 3134/4885MAOA 3406/4885PTPN1 816/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | MAOB 2601/4885MAOA 2780/4885PTPN1 2161/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | MAOB 1796/4885MAOA 3127/4885PTPN1 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.